Profile
Sector:
HealthcareCountry:
United StatesIPO:
03 February 2011Website:
http://www.pacira.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 20:20:00 GMTDividend
Analysts recommendations
Institutional Ownership
PCRX Latest News
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?
Pacira (PCRX) receives the FDA's RMAT designation for its gene-therapy product candidate, PCRX-201, which is currently being developed in an early-stage study to treat osteoarthritis of the knee.
Pacira (PCRX) reports fourth-quarter 2023 results, wherein earnings match and revenues beat estimates, driven by strong Exparel sales.
Pacira (PCRX) came out with quarterly earnings of $0.89 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.80 per share a year ago.
Pacira (PCRX) announces weaker-than-expected third-quarter 2023 results. The company streamlines its 2023 guidance for net Exparel sales.
Pacira (PCRX) announces weaker-than-expected second-quarter 2023 results. The company updates its 2023 financial guidance.
Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Susan Mesco - Head of IR David Stack - Chairman & CEO Charles Reinhart - CFO Conference Call Participants David Amsellem - Piper Sandler Gregory Renza - RBC Capital Markets Glen Santangelo - Jefferies Rohit Bhasin - Needham & Company Boris Peaker - TD Cowen Operator Good day and thank you for standing by. Welcome to the Q2, 2023 Pacira BioSciences Inc. Earnings Conference Call.
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?
Pacira (PCRX) is witnessing strong growth on the back of its lead product, Exparel. Potential label expansion is set to boost sales in future quarters.
Pacira (PCRX) misses on Q1 earnings but beats on revenues, even though volume growth of Exparel is offset by lower selling prices.
What type of business is Pacira BioSciences?
Pacira BioSciences, Inc. is a holding biopharmaceutical company headquartered in Parsippany-Troy Hills, New Jersey, operating through a number of subsidiaries. It was founded in 2006 as Blue Acquisition Corp. It is a leading provider of non-opioid pain relief medications for patients and physicians, as well as non-opioid solutions for surgeons and anesthesiologists in the field of health regeneration. Pacira BioSciences is the only supplier of long-acting non-opioid analgesics. The company's product portfolio includes the following medications: EXPAREL and the iovera system. In addition, the company has a range of products and solutions at various stages of clinical development, such as DepoDexmedetomidine, DepoFoam-based local anesthetic, Pediatric infiltration, Lower extremity nerve block, and others.
What sector is Pacira BioSciences in?
Pacira BioSciences is in the Healthcare sector
What industry is Pacira BioSciences in?
Pacira BioSciences is in the Drug Manufacturers - Specialty & Generic industry
What country is Pacira BioSciences from?
Pacira BioSciences is headquartered in United States
When did Pacira BioSciences go public?
Pacira BioSciences initial public offering (IPO) was on 03 February 2011
What is Pacira BioSciences website?
https://www.pacira.com
Is Pacira BioSciences in the S&P 500?
No, Pacira BioSciences is not included in the S&P 500 index
Is Pacira BioSciences in the NASDAQ 100?
No, Pacira BioSciences is not included in the NASDAQ 100 index
Is Pacira BioSciences in the Dow Jones?
No, Pacira BioSciences is not included in the Dow Jones index
When does Pacira BioSciences report earnings?
The next expected earnings date for Pacira BioSciences is 02 August 2024